SBTX vs. NKTR, ERAS, NKTX, KMDA, ATAI, MRSN, ADCT, VSTM, AVIR, and PGEN
Should you be buying Silverback Therapeutics stock or one of its competitors? The main competitors of Silverback Therapeutics include Nektar Therapeutics (NKTR), Erasca (ERAS), Nkarta (NKTX), Kamada (KMDA), Atai Life Sciences (ATAI), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), Verastem (VSTM), Atea Pharmaceuticals (AVIR), and Precigen (PGEN). These companies are all part of the "pharmaceutical preparations" industry.
Silverback Therapeutics (NASDAQ:SBTX) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500.
Silverback Therapeutics has higher earnings, but lower revenue than Nektar Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nektar Therapeutics had 8 more articles in the media than Silverback Therapeutics. MarketBeat recorded 9 mentions for Nektar Therapeutics and 1 mentions for Silverback Therapeutics. Nektar Therapeutics' average media sentiment score of 0.18 beat Silverback Therapeutics' score of 0.00 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
Nektar Therapeutics has a consensus price target of $3.50, suggesting a potential upside of 100.00%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Silverback Therapeutics.
Nektar Therapeutics received 609 more outperform votes than Silverback Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Nektar Therapeutics an outperform vote while only 56.25% of users gave Silverback Therapeutics an outperform vote.
74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by insiders. Comparatively, 3.7% of Nektar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Silverback Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -195.02%. Silverback Therapeutics' return on equity of -29.62% beat Nektar Therapeutics' return on equity.
Summary
Nektar Therapeutics beats Silverback Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Silverback Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silverback Therapeutics Competitors List
Related Companies and Tools
